ZNTL vs. IRWD, IGMS, CYRX, PRLD, KURA, PBH, ARWR, XENE, CORT, and FOLD
Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Ironwood Pharmaceuticals (IRWD), IGM Biosciences (IGMS), Cryoport (CYRX), Prelude Therapeutics (PRLD), Kura Oncology (KURA), Prestige Consumer Healthcare (PBH), Arrowhead Pharmaceuticals (ARWR), Xenon Pharmaceuticals (XENE), Corcept Therapeutics (CORT), and Amicus Therapeutics (FOLD). These companies are all part of the "pharmaceutical preparations" industry.
Ironwood Pharmaceuticals (NASDAQ:IRWD) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.
In the previous week, Ironwood Pharmaceuticals had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 12 mentions for Ironwood Pharmaceuticals and 10 mentions for Zentalis Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.43 beat Zentalis Pharmaceuticals' score of -0.19 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.
Zentalis Pharmaceuticals has lower revenue, but higher earnings than Ironwood Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Ironwood Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500.
Zentalis Pharmaceuticals has a net margin of 0.00% compared to Zentalis Pharmaceuticals' net margin of -254.41%. Zentalis Pharmaceuticals' return on equity of -28.45% beat Ironwood Pharmaceuticals' return on equity.
Ironwood Pharmaceuticals presently has a consensus target price of $18.40, suggesting a potential upside of 192.06%. Zentalis Pharmaceuticals has a consensus target price of $31.67, suggesting a potential upside of 166.55%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Ironwood Pharmaceuticals is more favorable than Zentalis Pharmaceuticals.
Ironwood Pharmaceuticals received 452 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. However, 65.00% of users gave Zentalis Pharmaceuticals an outperform vote while only 61.09% of users gave Ironwood Pharmaceuticals an outperform vote.
Summary
Ironwood Pharmaceuticals beats Zentalis Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Zentalis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zentalis Pharmaceuticals Competitors List
Related Companies and Tools
